Chester County News and Community Website
WASHINGTON, D.C. — The U.S. Department of Energy announced Thursday a $625 million investment to renew its five National Quantum Information Science Research Centers, reaffirming President Trump’s push to keep …
U.S. Invests $625 Million to Cement Leadership in Quantum Technology Race Read More
PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) announced that the U.S. Food and Drug Administration has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adult patients …
GSK Wins FDA Approval for Blenrep Combo in Advanced Multiple Myeloma Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration announced a sweeping set of reforms and enforcement actions last week aimed at lowering prescription drug costs and protecting children from …
FDA Cracks Down on Unapproved Fluoride Drugs, Fast-Tracks Cheaper Biologic Alternatives Read More
WASHINGTON, D.C. — The U.S. Department of Labor announced a sweeping series of workforce and safety initiatives last week, including more than $86 million in grants to strengthen state training …
Labor Department Invests $86 Million in Workforce Training, Expands Mine Safety Grants Read More
WILMINGTON, DE — AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to their supplemental Biologics License Application (sBLA) for …
FDA Grants Priority Review for ENHERTU Combo in Advanced Breast Cancer Read More
KING OF PRUSSIA, PA — SEED Therapeutics, Inc. announced it has closed a $30 million Series A-3 financing and received U.S. Food and Drug Administration clearance of its Investigational New …
SEED Therapeutics Secures $30M Funding, Gains FDA Clearance for Lead Drug Read More
WILMINGTON, DE — Incyte (Nasdaq: INCY) announced that the U.S. Food and Drug Administration has approved Opzelura (ruxolitinib) cream 1.5% for children as young as two with mild to moderate …
FDA Expands Approval of Incyte’s Opzelura to Treat Pediatric Atopic Dermatitis Read More WILMINGTON, DE — The U.S. prescribing information for AIRSUPRA now includes results from the Phase IIIb BATURA trial, which demonstrated that the medication significantly reduced severe asthma exacerbations in patients …
AIRSUPRA Label Expanded With Evidence of Risk Reduction in Mild Asthma Read More
EXTON, PA — ProRx Pharma announced it has received a DEA Controlled Substances Registration Certificate, authorizing the company to handle and distribute select controlled substances. The certification expands ProRx’s ability …
ProRx Pharma Secures DEA Certification to Handle Controlled Substances Read More
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults …
FDA Approves Johnson & Johnson’s Tremfya Subcutaneous Induction for Ulcerative Colitis Read More